200956-20-3

Usage

Uses

Used in Pharmaceutical Industry:
1-(BENZYLOXY)-4-(2,2,2-TRIFLUOROETHOXY)BENZENE is used as a building block for the synthesis of various pharmaceuticals due to its unique chemical properties, contributing to the development of new medications.
Used in Agrochemical Industry:
In the agrochemical industry, 1-(BENZYLOXY)-4-(2,2,2-TRIFLUOROETHOXY)BENZENE is utilized as a component in the creation of agrochemicals, potentially enhancing crop protection and yield.
Used in Specialty Chemicals Production:
1-(BENZYLOXY)-4-(2,2,2-TRIFLUOROETHOXY)BENZENE is also used in the production of specialty chemicals, where its distinctive properties allow for the development of unique chemical products.
Used in Chemical Research:
1-(BENZYLOXY)-4-(2,2,2-TRIFLUOROETHOXY)BENZENE serves as a reagent in organic synthesis, facilitating chemical research and the exploration of new chemical reactions and processes.
It is crucial to handle 1-(BENZYLOXY)-4-(2,2,2-TRIFLUOROETHOXY)BENZENE with care due to potential health and safety risks if not properly managed.

InChI:InChI=1/C15H13F3O2/c16-15(17,18)11-20-14-8-6-13(7-9-14)19-10-12-4-2-1-3-5-12/h1-9H,10-11H2

Upstream product

• 103-16-2 4-Benzyloxyphenol 
• 6226-25-1 2,2,2-trifluoroethyl trifluoromethanesulphonate 
• 75-89-8 2,2,2-trifluoroethanol 
• 146631-00-7 [4-(benzyloxy)phenyl]boronic acid 
• 433-06-7 2,2,2-Trifluoroethyl p-toluenesulfonate 

Downstream Products

• 103-16-2 4-Benzyloxyphenol 
• 444341-81-5 3-bromopropyl 2-chloro-4-(2,2,2-trifluoroethoxy)phenyl ether 
• 444341-80-4 2-chloro-4-(2,2,2-trifluoroethoxy)phenol 
• 129560-99-2 4-(2,2,2-trifluoroethoxy)phenol 

Relevant academic research and scientific papers

THERAPEUTIC AGENT FOR INFLAMMATORY DISEASES, AUTOIMMUNE DISEASES, FIBROTIC DISEASES, AND CANCER DISEASES

A therapeutic agent for treating at least one disease selected from the group consisting of inflammatory diseases, autoimmune diseases, fibrotic diseases, and cancer diseases, comprising: at least one selected from the group consisting of a compound represented by the following general formula (1) and pharmacologically acceptable salts thereof as an active ingredient. [In the formula (1), R1 and R2 may be the same or different and each represents a hydrogen atom, a halogen atom, a hydroxyl group, a carboxy group, a cyano group, an optionally substituted C1-6 alkyl group et al.; R3 represents a hydrogen atom; R4 represents an optionally substituted 4- to 10-membered monocyclic heterocyclic group containing 1 to 4 heteroatoms selected from an oxygen atom, a nitrogen atom, and a sulfur atom; X represents a group represented by the following formula: -CH2-, - CH2-CH2-, -CH2-CH2-CH2-, or -CH2-O-CH2-; and Z represents a hydrogen atom or a hydroxyl group.]

NOVEL COMPOUND AND PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF

A compound represented by the general formula (1) below or a pharmacologically acceptable salt thereof: [In the formula (1), R1 and R2 may be the same or different and each represents a hydrogen atom, a halogen atom, a hydroxyl group, a carboxy group, a cyano group, an optionally substituted C1-6 alkyl group et al.; R3 represents a hydrogen atom; R4 represents an optionally substituted 4- to 10-membered monocyclic heterocyclic group containing 1 to 4 heteroatoms selected from an oxygen atom, a nitrogen atom, and a sulfur atom; X represents a group represented by the following formula: —CH2—, —CH2—CH2—, —CH2—CH2—CH2—, or —CH2—O—CH2—; and Z represents a hydrogen atom or a hydroxyl group.]

Facile synthesis of trifluoroethyl aryl ethers through copper-catalyzed coupling of CF3CH2OH with aryl- and heteroaryl boronic acids

An efficient copper-catalyzed Chan-Lam reaction of trifluoroethanol with a variety of aryl- and heteroaryl boronic acids has been developed. This research provides a practical method to synthesize trifluoroethyl aryl ethers in moderate to good yields under mild conditions.

Base mediated deprotection strategies for trifluoroethyl (TFE) ethers, a new alcohol protecting group

A trifluoroethyl (TFE) ether is specifically introduced as a protecting group in organic chemistry. Its first strategic application and removal in the total synthesis of vinigrol is discussed. Two lithium base mediated deprotection strategies for its removal are presented in this Letter. In one deprotection approach, the trifluoroethyl ether is converted to a difluorovinyl ether and then catalytically cleaved using osmium tetraoxide, while in the second approach a difluorovinyl anion is formed and trapped with an electrophilic oxygen reagent (MoOPH) to form a labile difluoroacetate. To further aid the reader, a summary of approaches for forming trifluoroethyl ethers is included as well as a discussion of alternate deprotection strategies.

(2R)-2-Methylchromane-2-carboxylic acids: Discovery of selective PPARα agonists as hypolipidemic agents

A SAR study was conducted on chromane-2-carboxylic acid toward selective PPARα agonisim. As a result, highly potent, and selective PPARα agonists were discovered. The optimized compound 43 exhibited robust lowering of total cholesterol levels in hamster and dog animal models.

Benzopyrancarboxylic acid derivatives for the treatment of diabetes and lipid disorders

A class of benzopyrancarboxylic acid derivatives comprises compounds that are potent agonists of PPAR alpha and/or gamma, and are therefore useful in the treatment, control or prevention of non-insulin dependent diabetes mellitus (NIDDM), hyperglycemia, d